Trial Profile

Regorafenib and Nivolumab Simultaneous Combination Therapy for Advanced and Metastatic Solid Tumors: Phase I Clinical Trial

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 29 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary) ; Regorafenib (Primary)
Indications Colorectal cancer; Gastric cancer; Liver cancer; Solid tumours
Focus Adverse reactions
Acronyms REGONIVO

Most Recent Events

09 Jun 2022 Results of updated efficacy outcomes from REGONIVO plus LENPEM cohort published in the Clinical Cancer Research
23 Apr 2021 Status changed from active, no longer recruiting to completed.
09 Sep 2020 Planned End Date changed from 31 Jul 2022 to 30 Apr 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com